HOWL — Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL) is a biotechnology company listed on NASDAQ. It is led by Daniel J. Hicklin Ph.D., based in 200 Talcott Ave, Watertown, MA, United States, 02472, with about 46 employees. Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Net income was -$16.4M. HOWL currently screens at market cap $48.9M.

Use this HOWL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the HOWL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the HOWL SEC filings page. Lician reads the product cache first so this HTML stays unique to Werewolf Therapeutics Inc even when a live quote feed is slow.